Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

PDUFA Negotiations Begin With FDA Seeking Review System Reform

This article was originally published in The Pink Sheet Daily

Executive Summary

Fee structure changes and process enhancements floated during opening session between industry and agency.


Related Content

FDA Safety Reports: Firms Want Advance Notice Before Public Release
FDA's Ongoing User Fee System Upgrade Limits Payment Options
PDUFA VI: FDA Wary Of Industry Proposals With More Metrics
PDUFA VI: FDA Wary Of Industry Proposals With More Metrics
PDUFA VI Might Adjust Establishment Fees; FDA Aims For Simplification
Breakthrough Requests: FDA Adds Quick Screen To Pare Workload
PDUFA VI: BIO Survey Finds FDA Communication Problems
PDUFA Budgeting: What Will Get Added, Subtracted – Or Multiplied By Cures?
PDUFA VI: Price Tag For Patient Experience Data Validation May Go Up
‘Breakthrough’ Fee Eyed As Deterrent To Frivolous Requests